Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.40 |
| ▸ | PDE6C | P51160 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447286 | 0.88 | MEN1 (0.39) | PDE5APDE6CNR3C1L3MBTL1ALDH1A1 | |
| SCHEMBL7241286 | 0.87 | PDE5A (0.44) | PDE5APDE6CALDH1A1MAPK1NPC1 | |
| SCHEMBL6446798 | 0.86 | PDE5A (0.39) | PDE5APDE6CNR3C1ALDH1A1MEN1 | |
| SCHEMBL6444896 | 0.84 | PDE5A (0.62) | PDE5APDE6CALDH1A1KMT2A | |
| SCHEMBL6777123 | 0.82 | PDE5A (0.47) | PDE5ANR3C1L3MBTL1ALDH1A1NPC1 | |
| SCHEMBL6356420 | 0.80 | PDE5A (0.38) | PDE5APDE6CNR3C1L3MBTL1ALDH1A1 | |
| SCHEMBL6444195 | 0.79 | PDE5A (0.56) | PDE5APDE6CALDH1A1KMT2A | |
| SCHEMBL6443433 | 0.78 | PDE5A (0.56) | PDE5APDE6CALDH1A1KMT2A | |
| SCHEMBL6199773 | 0.78 | HDAC1 (0.43) | PDE5APDE6CMAPK1GAA | |
| SCHEMBL7240689 | 0.78 | RXFP1 (0.47) | L3MBTL1ALDH1A1MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1371647-A2 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1073658-B1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6458951-B2 | FOR TREATMENT OF MALE ERECTILE DYSFUNCTION, FEMALE SEXUAL DYSFUNCTION | PFIZER INC | 2002-10-01 | — | — | US | disclosed |
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | BUNNAGE MARK EDWARD (GB) | 2001-11-08 | — | — | US | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 21/4885NR3C1 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.